troglitazone has been researched along with Diabetic Angiopathies in 13 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "Troglitazone treatment resulted in an average 75% increase in the adiponectin levels, but no changes were observed in the endothelium-dependent vasodilation, any other measurement of vascular reactivity, or any other markers of endothelial activation." | 2.71 | Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. ( Buras, J; Horton, ES; Orlow, D; Reenstra, WR; Veves, A, 2005) |
| "Troglitazone therapy was associated with increases in LDL size (26." | 2.70 | Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. ( Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raji, A | 1 |
| Plutzky, J | 1 |
| Caballero, AE | 1 |
| Saouaf, R | 1 |
| Lim, SC | 1 |
| Hamdy, O | 1 |
| Abou-Elenin, K | 1 |
| O'Connor, C | 1 |
| Logerfo, FW | 1 |
| Horton, ES | 2 |
| Veves, A | 2 |
| Muniyappa, R | 1 |
| El-Atat, F | 1 |
| Aneja, A | 1 |
| McFarlane, SI | 1 |
| Verrier, E | 1 |
| Wang, L | 1 |
| Wadham, C | 1 |
| Albanese, N | 1 |
| Hahn, C | 1 |
| Gamble, JR | 1 |
| Chatterjee, VK | 1 |
| Vadas, MA | 1 |
| Xia, P | 1 |
| Jawa, AA | 1 |
| Fonseca, VA | 1 |
| Buras, J | 1 |
| Reenstra, WR | 1 |
| Orlow, D | 1 |
| Katayama, S | 1 |
| Murakami, T | 1 |
| Mizuno, S | 1 |
| Ohsato, K | 1 |
| Moriuchi, I | 1 |
| Arai, Y | 1 |
| Nio, Y | 1 |
| Kaku, B | 1 |
| Takahashi, Y | 1 |
| Ohnaka, M | 1 |
| Zimmet, P | 1 |
| Collier, G | 1 |
| Takagi, T | 1 |
| Akasaka, T | 1 |
| Yamamuro, A | 1 |
| Honda, Y | 1 |
| Hozumi, T | 1 |
| Morioka, S | 1 |
| Yoshida, K | 1 |
| Marcus, AO | 1 |
| Chu, NV | 1 |
| Kong, AP | 1 |
| Kim, DD | 1 |
| Armstrong, D | 1 |
| Baxi, S | 1 |
| Deutsch, R | 1 |
| Caulfield, M | 1 |
| Mudaliar, SR | 1 |
| Reitz, R | 1 |
| Henry, RR | 1 |
| Reaven, PD | 1 |
| Makino, N | 1 |
| Hirayama, H | 1 |
| Yonemochi, H | 1 |
| Yano, K | 1 |
| Abe, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
5 reviews available for troglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies | 2002 |
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies | 2005 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio | 1999 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2000 |
6 trials available for troglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Topics: Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fasting; Female; | 2003 |
The Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Ang | 2003 |
Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
Topics: Adiponectin; Adult; Aged; Brachial Artery; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2005 |
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
Topics: Cell Division; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2000 |
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Chromans; D | 2002 |
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; | 2001 |
2 other studies available for troglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
Topics: Animals; Aorta; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Chromans; Diabetic | 2004 |
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
Topics: Angina Pectoris, Variant; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Humans; Insulin Re | 1999 |